New Opportunities in AI Drug Development? Wall Street "Trending" Institution Lists 3 Companies!

A group of stock research analysts recently ventured into a new field: they had Claude help them develop new drugs.

As a result, 211 designs were sent to the lab, and 17 of them passed the binding tests set by the research team. Although it's still far from becoming an actual drug, this attempt opened up an investment clue worth the attention of U.S. stock investors.

This Wall Street influencer institution, Citrini, spent about $200,000 on the project, including around $50,000 on computing and nearly $150,000 on synthesis, protein production, and testing expenses.

Where the money is spent, opportunities are worth seeking.

Following this R&D expenditure reveals specific investment opportunities: Who is responsible for validating the effects? Who provides testing tools? Who enables laboratories to operate more efficiently? These steps could all take on new orders. Next, we break down several related companies to see where their opportunities lie.

The more capable AI becomes at design, the busier the labs may get

The most interesting aspect of this experiment was the contrast in speed.

Claude completed the first-round designs in about 64 hours, but the first batch of laboratory results took about 39 days. Computers can quickly generate plans, but synthesis, cultivation, detection, and validation in reality require equipment, personnel, and time.

For investors, this provides another way to participate in AI-powered drug development.

When betting on a pharmaceutical development company, you usually have to judge whether its candidate drugs can pass clinical trials. With laboratory service providers, however, you can observe much earlier whether customers are increasing procurement, if their equipment is busier, and if orders are growing.

According to US Stock Investment Network, the most valuable segments to explore at this stage are those that can turn AI R&D activities into actual revenue. Different companies occupy different positions, and their opportunities vary in focus.

CRL: Focus on order recovery and subsequent validation demands

Charles River Laboratories ($CRL) is Citrini's highest-conviction pick, mainly providing drug discovery, preclinical research, and safety evaluation services.

AI can help researchers propose more candidate solutions, but which are worth further development and whether there are safety issues still have to be answered through experiments. As valid projects move forward, CRL gets the chance to take on follow-up research needs.

There’s also an immediate highlight: the company’s legacy business orders have already shown improvement.

In Q2 2026, the company saw only 0.2% organic growth in discovery and safety evaluation, but management indicated that the net book-to-bill ratio reached its highest level in nearly four years.

These data points are best evaluated together: revenue hasn't accelerated noticeably, but orders are showing positive changes first. Going forward, if orders gradually convert to revenue and add to new projects driven by AI, the company's growth potential will become much clearer.

Therefore, what’s worth tracking for CRL is how far the recovery in their core business can go, and whether new research demands can be sustained.

RVTY: The more complex the experiments, the more important the detection tools

Revvity ($RVTY) provides cell analysis, screening, detection, and research software, helping researchers determine what effects a candidate molecule actually produces and whether further investment is warranted.

If AI enables a team to study more solutions in parallel, the following steps include batch testing, comparing results, and compiling data. Devices and software that can improve efficiency in this part will have a more clearly demonstrated procurement value.

I value the sustainability of this type of business: once the equipment is installed in the lab, if the usage frequency increases, related reagents, consumables, and services may continually generate demand.

So for RVTY, in addition to watching instrument orders, it’s important to look at whether customers continue to ramp up usage and purchases after the equipment is sold. This, more than one-time equipment sales, indicates whether the demand is solid.

Tecan: Helping laboratories keep up with the speed of AI

Swiss-listed company Tecan mainly provides lab automation and liquid handling equipment.

When research teams handle larger numbers of samples, pipetting, aliquoting, and performing repetitive processes consume tremendous time. Automated equipment helps labs expand their capacity and reduces errors in repetitive operations.

This company has also made a concrete advancement: Anthropic has disclosed that Tecan is adding relevant standard support for the Fluent liquid handling platform, enabling AI agents to discover and operate the equipment.

This means the scope of AI’s participation in R&D can extend from proposing solutions to actually coordinating equipment execution of experiments.

This partnership is still in its early stages, but the direction is noteworthy. For Tecan, the next most valuable outcome would be seeing these capabilities incorporated into more customers’ daily operations, driving equipment upgrades and procurement.

TWST is also worth watching, but distinguish between beneficiary and entry point

When talking about this industry chain, you can’t leave out Twist Bioscience ($TWST).

It directly participated in Citrini’s protein production and testing for this project. With AI generating designs and customers purchasing lab services, this business model has already taken shape in the project.

Thus, if you want to observe how AI-generated designs are turning into actual purchases, TWST offers a straightforward window.

However, the extent of business benefit and stock investment returns are still separated by the entry price. What needs to be judged is how much additional income and profit new orders can bring to the company, and how much growth is already reflected in the share price.

This sector is worth adding to your research watch list ahead of time

My judgment is that companies providing AI drug discovery tools, testing, and lab services are worth tracking as an independent sector.

Watch CRL for order recovery and follow-up validation demand, RVTY for detection activity and recurring purchases, Tecan for automation penetration, and TWST for the speed at which designs turn into synthesis and lab orders.

The critical premise is only one: customers truly willing to increase R&D investment. No matter how many AI-generated solutions exist, only when they make it into procurement budgets will they become actual business for listed companies.

For ordinary investors, the more practical way is to first add these companies to your watch list and then observe in financial reports whose orders, consumables revenue, and profits begin to sustainably improve.

It may still take a long time until a new AI-developed drug is finally marketed. But companies providing tools and services for research and development already have trackable orders. Whether the opportunities are real, we can start judging from these orders.

StockWe AI "Finance Expert Group" is here!

After a busy day, you open the quote screen and realize your favorite U.S. stock has already surged or plunged.

You quickly check announcements and news, hoping to figure out what happened.

But what if there was an AI finance expert group that could watch the market 24/7 for you—and even proactively complete the analysis?

StockWe AI "Finance Expert Group" is here!

Standing by at any time are five professional experts:

📊 Individual Stock Research Expert

📈 Industry Research Expert

🌍 Macro Economy Research Expert

💼 Wealth Management Expert

📝 Real-Time Trading Assistant

Most critical: Collaborative work!

See a few real scenarios 👇

① A U.S. stock suddenly soars or plunges?

You set which symbols and conditions to track.

Once triggered, the market monitoring expert can automatically summon the stock research expert to analyze price moves, fundamentals shifts, and further focus metrics.

You only need to build your U.S. stock symbol monitoring pool. Our quantitative AI system will continuously track:

Key developments such as news, analyst ratings, insider trades, short interest, option activity, dark pool trades, block trades, earnings forecasts, and sudden price swings.

For example, if you follow NVDA, you can check how many news articles came out today, whether there was option activity, and if dark pool and block trades changed—just click to view directly.

Even better, once you enable app notifications, you receive instant push alerts whenever watched stocks show new developments.

Previously, you needed to chase information everywhere. Now you can hand your stocks to the system for 24/7 monitoring.

For long-term investors, this is an individual stock alert system;

For swing and options traders, it's a real-time activity radar.

Enter the ticker, never miss another key development.

Click the original link to download the App